C61Malignant neoplasm of prostate

C61 is the ICD-10-CM diagnosis code for malignant neoplasm of prostate. It belongs to block C60-C63 (malignant neoplasms of male genital organs) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Don't report C61 together with the conditions in its Excludes1 note: malignant neoplasm of seminal vesicle (C63.7).

Use an additional code, if applicable, to identify: hormone sensitivity status (Z19.1-Z19.2) and rising PSA following treatment for malignant neoplasm of prostate (R97.21).

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 715 (Male Reproductive System and Other O.R. Procedures for Malignancy with CC/MCC, relative weight 2.2906), DRG 716 (Male Reproductive System and Other O.R. Procedures for Malignancy without CC/MCC, relative weight 1.4619), DRG 722 (Malignancy, Male Reproductive System with MCC, relative weight 1.6689), DRG 723 (Malignancy, Male Reproductive System with CC, relative weight 1.0697) and DRG 724 (Malignancy, Male Reproductive System without CC/MCC, relative weight 0.5901), in MDC 12 (Diseases and Disorders of the Male Reproductive System), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is on the CMS list of diagnoses consistent only with male patients (the sex-conflict edit itself was retired in FY2025).

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as 185 (malignant neoplasm of prostate).